ATE370735T1 - Phenylpyridazinderivate und diese enthaltende arzneimittel - Google Patents

Phenylpyridazinderivate und diese enthaltende arzneimittel

Info

Publication number
ATE370735T1
ATE370735T1 AT01947902T AT01947902T ATE370735T1 AT E370735 T1 ATE370735 T1 AT E370735T1 AT 01947902 T AT01947902 T AT 01947902T AT 01947902 T AT01947902 T AT 01947902T AT E370735 T1 ATE370735 T1 AT E370735T1
Authority
AT
Austria
Prior art keywords
group
diseases
substituted
products containing
containing same
Prior art date
Application number
AT01947902T
Other languages
English (en)
Inventor
Masao Ohkuchi
Yoshinori Kyotani
Hiromichi Shigyo
Tomoyuki Koshi
Tadaaki Ohgiya
Takayuki Matsuda
Natsuyo Kumai
Kyoko Yasuoka
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Application granted granted Critical
Publication of ATE370735T1 publication Critical patent/ATE370735T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/12—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/18—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT01947902T 2000-07-10 2001-07-06 Phenylpyridazinderivate und diese enthaltende arzneimittel ATE370735T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/612,953 US6664256B1 (en) 2000-07-10 2000-07-10 Phenylpyridazine compounds and medicines containing the same

Publications (1)

Publication Number Publication Date
ATE370735T1 true ATE370735T1 (de) 2007-09-15

Family

ID=24455274

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01947902T ATE370735T1 (de) 2000-07-10 2001-07-06 Phenylpyridazinderivate und diese enthaltende arzneimittel

Country Status (15)

Country Link
US (1) US6664256B1 (de)
EP (1) EP1300399B1 (de)
JP (1) JP4915715B2 (de)
KR (1) KR100777623B1 (de)
CN (1) CN1272326C (de)
AT (1) ATE370735T1 (de)
AU (2) AU6947401A (de)
CA (1) CA2413042A1 (de)
DE (1) DE60130119T2 (de)
HU (1) HUP0301230A3 (de)
NO (1) NO324219B1 (de)
NZ (1) NZ523242A (de)
RU (1) RU2269519C2 (de)
TW (1) TW593285B (de)
WO (1) WO2002004427A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU738595B2 (en) * 1997-11-19 2001-09-20 Kowa Co., Ltd. Novel pyridazine derivatives and medicines containing the same as effective ingredients
CA2461806A1 (en) * 2001-09-26 2003-04-03 Kowa Co., Ltd. Water-soluble phenylpyridazine derivatives and medicines containing the same
PL375552A1 (en) 2002-05-22 2005-11-28 Amgen Inc. Vanilloid receptor ligands and their medical applications
CA2493667C (en) 2002-08-08 2010-04-27 Amgen Inc. Vanilloid receptor ligands and their use in treatments
EP1688408A3 (de) * 2002-08-08 2007-08-22 Amgen, Inc Vanilloidrezeptorliganden und deren Verwendung bei Behandlungen
RU2328495C2 (ru) * 2003-03-07 2008-07-10 Кова Ко., Лтд. Производное бензофурана
RU2005132167A (ru) * 2003-03-18 2006-05-10 Кова Ко., Лтд. (Jp) Водорастворимые производные фенилпиридазина и лекарственные средства, содержащие их
JPWO2005012259A1 (ja) * 2003-07-30 2007-09-27 興和株式会社 オステオポンチン産生抑制方法
PL1668105T3 (pl) 2003-09-29 2019-03-29 Deb Ip Limited Kompozycje żelopodobne i pieniące o dużej zawartości alkoholu
BRPI0513359A (pt) 2004-07-15 2008-05-06 Amr Technology Inc tetraidroisoquinolinas substituìdas por arila e heteroarila e uso destes para bloquear a recaptação de norepinefrina, dopamina, e serotonina
DE102004062775A1 (de) 2004-12-21 2006-06-29 Stockhausen Gmbh Alkoholischer Pumpschaum
CN101170904A (zh) 2005-03-07 2008-04-30 戴博全球保健有限公司 含有有机硅基表面活性剂的高醇含量发泡组合物
CA2606288A1 (en) * 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
US7772233B2 (en) * 2006-04-19 2010-08-10 Merck Serono, S.A. Arylamino N-heteroaryl compounds as MEK inhibitors
US8580860B2 (en) * 2007-02-23 2013-11-12 Gojo Industries, Inc. Foamable alcoholic composition
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
AR071997A1 (es) * 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
MX2011011901A (es) 2009-05-12 2012-01-20 Albany Molecular Res Inc Tetrahidroisoquinolinas aril, heteroaril, y heterociclo sustituidas y uso de las mismas.
WO2011103091A1 (en) * 2010-02-18 2011-08-25 Transtech Pharma, Inc. Phenyl-heteroaryl derivatives and methods of use thereof
GB2497476B (en) 2010-09-06 2018-01-10 Guangzhou Inst Biomed & Health Amide Compounds
GB201106829D0 (en) 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
WO2012111024A1 (en) 2011-02-18 2012-08-23 Suven Nishtaa Pharma Pvt Ltd Pharmaceutical compositions of dexlansoprazole
JP7738910B2 (ja) * 2020-03-27 2025-09-16 テンヴィー・セラピューティクス，インコーポレーテッド 置換ピリダジン化合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3840597A (en) 1971-02-24 1974-10-08 Riker Laboratories Inc Substituted 2-phenoxy alkane-sulfonanilides
US4092311A (en) * 1976-06-03 1978-05-30 American Cyanamid Company Hypotensive alkyl-3-[6-(aryl)-3-pyridazinyl]-carbazates
JPH0753725B2 (ja) 1987-10-08 1995-06-07 富山化学工業株式会社 ４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
FI91062C (fi) 1988-12-28 1994-05-10 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisten naftaleenijohdannaisten valmistamiseksi
JPH06501926A (ja) * 1990-08-06 1994-03-03 藤沢薬品工業株式会社 複素環式化合物
IL104369A0 (en) 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
DK0628550T3 (da) * 1993-06-08 1998-09-28 Vertex Pharma Pyridazin som interleukin-1 beta-omdannede enzyminhibitorer
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
WO1997005878A1 (en) 1995-08-10 1997-02-20 Merck & Co., Inc. 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
DE69825154T2 (de) 1997-03-14 2005-07-21 Merck Frosst Canada & Co, Kirkland Pyridazinone als inhibitoren von cyclooxygenase-2
BR9812127A (pt) 1997-08-22 2000-07-18 Abbott Lab Arilpiridazinonas como inibidores da biossìntese de prostagleina endoperóxido h sintase
PT1005460E (pt) 1997-08-22 2006-07-31 Abbott Lab Biossintese de inibidores de prostaglandina-endoperoxido h-sintase
JP3999861B2 (ja) * 1997-11-19 2007-10-31 興和株式会社 新規ピリダジン誘導体及びこれを有効成分とする医薬
AU738595B2 (en) 1997-11-19 2001-09-20 Kowa Co., Ltd. Novel pyridazine derivatives and medicines containing the same as effective ingredients
WO1999032448A1 (en) * 1997-12-19 1999-07-01 Amgen Inc. Substituted pyridine and pyridazine compounds and their pharmaceutical use
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
CZ300570B6 (cs) 1998-10-27 2009-06-17 Abbott Laboratories Inhibitory biosyntézy prostaglandin endoperoxid H synthasy
US6350744B1 (en) * 1998-11-20 2002-02-26 Merck & Co., Inc. Compounds having cytokine inhibitory activity
US6602872B1 (en) 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity

Also Published As

Publication number Publication date
CN1272326C (zh) 2006-08-30
US6664256B1 (en) 2003-12-16
EP1300399A4 (de) 2004-02-11
AU6947401A (en) 2002-01-21
HUP0301230A3 (en) 2004-03-29
RU2269519C2 (ru) 2006-02-10
NO324219B1 (no) 2007-09-10
KR100777623B1 (ko) 2007-11-27
NO20030097D0 (no) 2003-01-09
NZ523242A (en) 2004-10-29
HUP0301230A2 (hu) 2003-12-29
AU2001269474B2 (en) 2005-09-15
DE60130119D1 (de) 2007-10-04
CA2413042A1 (en) 2002-01-17
JP4915715B2 (ja) 2012-04-11
TW593285B (en) 2004-06-21
NO20030097L (no) 2003-01-09
WO2002004427A1 (en) 2002-01-17
CN1440392A (zh) 2003-09-03
EP1300399A1 (de) 2003-04-09
EP1300399B1 (de) 2007-08-22
DE60130119T2 (de) 2007-12-13
KR20030007948A (ko) 2003-01-23

Similar Documents

Publication Publication Date Title
ATE370735T1 (de) Phenylpyridazinderivate und diese enthaltende arzneimittel
DE60017115D1 (de) Amid-derivate und deren medizinische verwendung
DE60009929D1 (de) Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung
ATE556048T1 (de) Prolinderivate und ihre verwendung als heilmittel
ATE293603T1 (de) Piperazin-verbindungen und ihre medizinische verwendung
HUP0401729A2 (hu) IV típusú foszfodiészteráz inhibitor hatású alkin-aril-naftiridin-4(1H)-on-származékok és ezeket tartalmazó gyógyszerkészítmények
FI935529A0 (fi) Aminometylensubstituerade icke-aromatiska heterocykliska foereningar
NO20021358D0 (no) Alkylendiamin-substituerte heterocykler
NZ514037A (en) 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of CNS disorders
WO2000064874A3 (en) Heterosubstituted pyridine derivatives as pde 4 inhibitors
EP1142881A4 (de) Pyrimidinderivate als inhibitoren der poly(adp-ribose)-polymerase
KR880002829A (ko) 디하이드로피리딘 항알러지제 및 소염제
AU8811401A (en) Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
DE60022986D1 (de) Pyridazin-3-on-derivate und sie enthaltende Arzneimittel
NO20022123L (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII
ATE209633T1 (de) Pyridinderivate,als arzneimittel zur behandlung von geschwüren und als antibakterielle mittel
MXPA03010583A (es) Derivados de pirimidina utiles como inhibidores de cox-2 selectivos.
DE69925160D1 (de) Arylpiperidin- und aryl-1,2,5,6-tetrahydropyridinamid-derivate mit 5ht1a rezeptor aktivität
PT1140925E (pt) 3,4-di-hidro-2h-benzo¬1,4|oxazinil-metil-¬3-(1h-indol-3il)-alquil|-aminas
ATE512139T1 (de) Wasserlösliche phenylpyridazinderivate und diese enthaltende arzneimittel
EP2266566A3 (de) Nicotinamid Derivate und ihrer Verwendung als Therapeutika
ATE275560T1 (de) Bemzimidazolverbindungen und medikamente die diese enthalten
EP1389619A4 (de) Pkb-3564-substanz mit die gefässneubildung hemmender wirkung
CA2245896A1 (en) A therapeutic agent for renal disease
ATE262522T1 (de) Benzimidazolverbindungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties